Polymorphisms and patent, market, and legal battles: Cefdinir case study

被引：59
作者：
Cabri, Walter [1 ]
Ghetti, Paolo [1 ]
Pozzi, Giovanni [1 ]
Alpegiani, Marco [1 ]
机构：
[1] Antibioticos SpA, Res & Dev, I-20089 Milan, Italy
来源：
ORGANIC PROCESS RESEARCH & DEVELOPMENT | 2007年 / 11卷 / 01期
关键词：
D O I：
10.1021/op0601060
中图分类号：
O69 [应用化学];
学科分类号：
081704 ;
摘要：
The ongoing patent battle relating to Cefdinir polymorphism and crystalline forms is described from a scientific point of view. This case study illustrates some of the strategies adopted by generic bulk manufacturers to challenge originator's patents on polymorphic forms.
引用
收藏
页码：64 / 72
页数：9
相关论文
共 37 条
[1]  
Bernstein J., 2020, Polymorphism in Molecular Crystals, Vsecond, DOI 10.1093/oso/9780199655441.001.0001
[2]  
Byrn S.R., 1999, Solid State Chemistry of Drugs, VSecond
[3]  
CANDIANI I, 2002, Patent No. 6680327
[4]  
Chandrasekaran R., 2005, World Patent Application, Patent No. [WO2005/090360, 2005090360]
[5]  
CVAK L, 2004, Patent No. 04101510
[6]  
DAEMON O, 2005, Patent No. 20060122165
[7]  
DANDALA S, 2004, Patent No. 20050137182
[8]  
DESHPANDE PB, 2003, Patent No. 2004046154
[9]  
DUERST RW, 2003, Patent No. 20050059818
[10]  
DUERST RW, 2003, Patent No. 2003000661148
1234